MediGene AG

FRA:MDG1 ISIN:DE000A161NA3

Medigene AGMedigene AG (FRA:MDG1) is a biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

 
   
 

View in Other Languages

News

Medigene AG (FRA:MDG1) Sells Partial Stake in Immunocore

🕔4/5/2016 12:31:07 PM 4933

Medigene AG (FRA:MDG1), a clinical stage immune-oncology company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announces that it has today sold 50% of its' stake in the private biotech company Immunocore Ltd., UK, for approximately 4.9 million GBP (approx. EUR 6.1 million).

Read Full Article

MediGene AG (FRA:MDG) MediGene Publishes 9-Months-Report 2008 - Sales And EBITDA Increased

🕔11/7/2008 5:33:00 PM 4615

MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (FRA:MDG) MediGene To Present At The Rodman & Renshaw Healthcare Conference In New York And At The German Equity Forum In Frankfurt

🕔11/6/2008 6:35:00 PM 3554

MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (FRA:MDG) MediGene Announces Change To Supervisory Board

🕔11/1/2008 6:03:00 AM 3651

MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (FRA:MDG) MediGene Reports Positive Final Results From EndoTAG(TM)-1 Phase II Study In Pancreatic Cancer

🕔10/20/2008 4:31:00 PM 3485

MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (FRA:MDG) MediGene: RhuDex(TM) To Be Examined In Further Laboratory Tests

🕔10/17/2008 4:33:00 PM 3405

MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (FRA:MDG) MediGene Spins Out Mtcr Programme - Independent Company Immunocore
Limited Founded

🕔10/1/2008 5:05:01 PM 2962

MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (OJ:MDG) Clinical Data For EndoTAG(TM)-1 To Be Presented At Two Further Medical Conferences (DGVS, UEGW)

🕔9/29/2008 7:33:00 PM 2499

MediGene AG (OJ:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (OJ:MDG) MediGene To Present At UBS Global Life Science Conference In New York

🕔9/22/2008 8:01:01 PM 2344

MediGene AG (OJ:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

MediGene AG (OJ:MDG) MediGene Reports Positive 12-month Survival Data For EndoTAG(TM)-1 from Phase II Pancreatic Cancer Study

🕔9/16/2008 6:07:00 PM 2350

MediGene AG (OJ:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article
###

12,813 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 8) (Last 30 Days: 62) (Since Published: 8436) 

Company Data

    Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.medigene.com

Social Media